Remarkable clinical outcomes have been achieved in cancer immunotherapy of several types of cancers based on ICB antibodies, especially those blockading the programmed cell death protein 1/programmed death-ligand 1 (PD-1/PD-L1) or cytotoxic T lymphocyte antigen 4 (CTLA-4) pathway. Here, PDCD1 is linked to cancer.